Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Neoplasms of the CNS

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 42 articles:
HTML format
Text format



Single Articles


    March 2020
  1. JAKSCH-BOGENSPERGER H, Spiegl-Kreinecker S, Arosio P, Eckl P, et al
    Ferritin in glioblastoma.
    Br J Cancer. 2020 Mar 23. pii: 10.1038/s41416-020-0808.
    PubMed     Text format     Abstract available


  2. ENGEL AL, Lorenz NI, Klann K, Munch C, et al
    Serine-dependent redox homeostasis regulates glioblastoma cell survival.
    Br J Cancer. 2020 Mar 17. pii: 10.1038/s41416-020-0794.
    PubMed     Text format     Abstract available


  3. PRUSS M, Dwucet A, Tanriover M, Hlavac M, et al
    Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma.
    Br J Cancer. 2020 Mar 2. pii: 10.1038/s41416-020-0759.
    PubMed     Text format     Abstract available


    December 2019
  4. SIMPSON AD, Soo YWJ, Rieunier G, Aleksic T, et al
    Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0677.
    PubMed     Text format     Abstract available


  5. BJORKBLOM B, Jonsson P, Tabatabaei P, Bergstrom P, et al
    Metabolic response patterns in brain microdialysis fluids and serum during interstitial cisplatin treatment of high-grade glioma.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0652.
    PubMed     Text format     Abstract available


    November 2019
  6. ZHANG G, Zhu Q, Fu G, Hou J, et al
    TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
    Br J Cancer. 2019 Nov 19. pii: 10.1038/s41416-019-0633.
    PubMed     Text format     Abstract available


    October 2019
  7. MULLER BARK J, Kulasinghe A, Chua B, Day BW, et al
    Circulating biomarkers in patients with glioblastoma.
    Br J Cancer. 2019 Oct 31. pii: 10.1038/s41416-019-0603.
    PubMed     Text format     Abstract available


    August 2019
  8. RAHMAN MA, Gras Navarro A, Brekke J, Engelsen A, et al
    Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
    Br J Cancer. 2019 Aug 15. pii: 10.1038/s41416-019-0551.
    PubMed     Text format     Abstract available


    March 2019
  9. KLOPFENSTEIN Q, Truntzer C, Vincent J, Ghiringhelli F, et al
    Cell lines and immune classification of glioblastoma define patient's prognosis.
    Br J Cancer. 2019 Mar 22. pii: 10.1038/s41416-019-0404.
    PubMed     Text format     Abstract available


  10. KAMIL M, Shinsato Y, Higa N, Hirano T, et al
    High filamin-C expression predicts enhanced invasiveness and poor outcome in glioblastoma multiforme.
    Br J Cancer. 2019 Mar 14. pii: 10.1038/s41416-019-0413.
    PubMed     Text format     Abstract available


  11. IJSSELSTEIJN ME, Petitprez F, Lacroix L, Ruano D, et al
    Revisiting immune escape in colorectal cancer in the era of immunotherapy.
    Br J Cancer. 2019 Mar 13. pii: 10.1038/s41416-019-0421.
    PubMed     Text format     Abstract available


    February 2019
  12. FOLTYN M, Luger AL, Lorenz NI, Sauer B, et al
    The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.
    Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-018-0368.
    PubMed     Text format     Abstract available


    January 2019
  13. GOEPPERT B, Roessler S, Renner M, Singer S, et al
    Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
    Br J Cancer. 2019;120:109-114.
    PubMed     Text format     Abstract available


    November 2018
  14. WANG S, O'Rourke DM, Chawla S, Verma G, et al
    Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma.
    Br J Cancer. 2018 Nov 27. pii: 10.1038/s41416-018-0342.
    PubMed     Text format     Abstract available


  15. BROWN NF, Carter TJ, Ottaviani D, Mulholland P, et al
    Harnessing the immune system in glioblastoma.
    Br J Cancer. 2018 Nov 5. pii: 10.1038/s41416-018-0258.
    PubMed     Text format     Abstract available


    September 2018
  16. ZIEGLER DS, Wong M, Mayoh C, Kumar A, et al
    Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
    Br J Cancer. 2018 Sep 17. pii: 10.1038/s41416-018-0251.
    PubMed     Text format     Abstract available


    August 2018
  17. KROL I, Castro-Giner F, Maurer M, Gkountela S, et al
    Detection of circulating tumour cell clusters in human glioblastoma.
    Br J Cancer. 2018 Aug 1. pii: 10.1038/s41416-018-0186.
    PubMed     Text format     Abstract available


    July 2018
  18. ROSEWEIR AK, Halcrow ES, Chichilo S, Powell AG, et al
    ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer.
    Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0174.
    PubMed     Text format     Abstract available


    March 2018
  19. DISNEY-HOGG L, Sud A, Law PJ, Cornish AJ, et al
    Influence of obesity-related risk factors in the aetiology of glioma.
    Br J Cancer. 2018 Mar 13. pii: 10.1038/s41416-018-0009.
    PubMed     Text format     Abstract available


    January 2018
  20. ZHANG W, Duan R, Zhang J, Cheung WKC, et al
    H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma.
    Br J Cancer. 2018 Jan 18. pii: bjc2017461. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  21. HOTTINGER AF, Ben Aissa A, Espeli V, Squiban D, et al
    Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
    Br J Cancer. 2018 Jan 9. pii: bjc2017469. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  22. GADGEEL S, Shaw AT, Barlesi F, Crino L, et al
    Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Br J Cancer. 2018;118:38-42.
    PubMed     Text format     Abstract available


    November 2017
  23. NANJO S, Hata A, Okuda C, Kaji R, et al
    Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
    Br J Cancer. 2017 Nov 30. pii: bjc2017394. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    October 2017
  24. YU CF, Chen FH, Lu MH, Hong JH, et al
    Dual roles of tumour cells-derived matrix metalloproteinase 2 on brain tumour growth and invasion.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  25. POYNTER JN, Richardson M, Roesler M, Krailo M, et al
    Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  26. TAY RY, Blackley E, McLean C, Moore M, et al
    Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
    Br J Cancer. 2017;117:921-924.
    PubMed     Text format     Abstract available


  27. BENKE G, Turner MC, Fleming S, Figuerola J, et al
    Occupational solvent exposure and risk of glioma in the INTEROCC study.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  28. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Text format     Abstract available


    August 2017
  29. ITO S, Koso H, Sakamoto K, Watanabe S, et al
    RNA helicase DHX15 acts as a tumour suppressor in glioma.
    Br J Cancer. 2017 Aug 22. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  30. ABDUL RAHIM SA, Dirkse A, Oudin A, Schuster A, et al
    Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.
    Br J Cancer. 2017 Aug 10. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  31. SHI C, Ren L, Sun C, Yu L, et al
    miR-29a/b/c function as invasion suppressors for gliomas by targeting CDC42 and predict the prognosis of patients.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  32. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  33. MACIACZYK D, Picard D, Zhao L, Koch K, et al
    CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
    Br J Cancer. 2017 Jun 1. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    May 2017
  34. PARAKH S, Park JJ, Mendis S, Rai R, et al
    Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
    Br J Cancer. 2017;116.
    PubMed     Text format     Abstract available


  35. DONG Z, Lei Q, Yang R, Zhu S, et al
    Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma.
    Br J Cancer. 2017 May 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  36. HAN S, Meng L, Jiang Y, Cheng W, et al
    Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  37. JOHANSEN C, Schuz J, Andreasen AS, Dalton SO, et al
    Study designs may influence results: the problems with questionnaire-based case-control studies on the epidemiology of glioma.
    Br J Cancer. 2017 Mar 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  38. KINSLER VA, O'Hare P, Jacques T, Hargrave D, et al
    MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.
    Br J Cancer. 2017 Mar 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  39. ANDERSEN KK, Duun-Henriksen AK, Frederiksen MH, Winther JF, et al
    Ninth grade school performance in Danish childhood cancer survivors.
    Br J Cancer. 2017;116:398-404.
    PubMed     Text format     Abstract available


    November 2016
  40. LLAGUNO SR, Parada LF
    Cell of origin of glioma: biological and clinical implications.
    Br J Cancer. 2016 Nov 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  41. WILLIAMS M, Treasure P, Greenberg D, Brodbelt A, et al
    Surgeon volume and 30 day mortality for brain tumours in England.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  42. GUPTA A, Roberts C, Tysoe F, Goff M, et al
    RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: